PharmaTelevision - Manuel Lopez-Figueroa, Vice President at Bay City Capital talks about their Investment philosophy and shares his views on the current climate of investment in biotechnology

Manuel Lopez-Figueroa, Vice President at Bay City Capital talks about their Investment philosophy and shares his views on the current climate of investment in biotechnology

Episode Loading...

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Manuel Lopez-Figueroa, Vice President at Bay City Capital talks about their Investment philosophy and shares his views on the current climate of investment in biotechnology

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Manuel Lopez-Figueroa, Vice President at Bay City Capital

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Types of investments

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BIO-Europe in Milan, in spring 2011. On this show I have Manuel Lopez-Figueroa, who is Vice President at Bay City Capital based in San Francisco, welcome to the show.

Manuel Lopez-Figueroa:

Good morning and thank you.

Fintan Walton:

Bay City Capital is a famous I suppose venture capital firm that has focused on the life sciences your role there is Vice President, could you describe to us the funds that Bay City Capital has under management and the types of investments that Bay City Capital normally does?

Manuel Lopez-Figueroa:

Yes, so basically helping around since 1997, we have five funds which are total of 1.7 billion under management, we have invested in about 85 companies and I can tell you little more about our people and our strategy.

Fintan Walton:

Sure, so the types of investments that you typically deal with your funds?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Manuel Lopez Figueroa

Vice President

Manuel Lopez-Figueroa, PhD, is Vice President at Bay City Capital and has been with the firm since July 2001. He specializes in evaluating investment opportunities with an emphasis on CNS. In addition, Dr. Lopez is the Scientific Liaison for the Pritzker Neuropsychiatric Disorders Research Consortium, a collaborative research enterprise comprised of a group of leaders in psychiatry, neuroscience and genetics from Stanford University, University of Michigan, Cornell University and the Universities of California at Davis and Irvine. The consortium aims to discover the neurobiological and genetic determinants of mood disorders and schizophrenia with the goal to develop novel diagnostics and therapeutics. Dr. Lopez is responsible for planning and directing all aspects of the consortium including strategy, R&D, legal (IP & contracts) and financial, to facilitate the commercialization of discoveries to fund additional research. Dr. Lopez has over 15 years of experience in the field of Neuroscience, has won numerous awards during his academic research career, and has published extensively. He completed post-doctoral work at the University of Michigan and at the University of Copenhagen, Denmark. Dr. Lopez received a PhD in Medicine and Surgery, and a MS in Molecular and Cell Biology from the Universities of Las Palmas and Universities of La Laguna, Spain respectively.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialization.

Bay City Capital

Bay City Capital LLC (Bay City Capital) was established in 1997 for the purpose of managing investment funds in the life sciences industry. Since that date, we've managed seven venture funds representing $1.6 billion in capital invested in over 85 companies. Five of these funds are general life sciences funds, and two are sector funds.